1Y Target$22.93Near-term target
5Y Target$32.11Compound horizon
10Y Target$47.21Long-dated conviction
FCF$326mTTM · 03/26CFCF $326m — modest; watch for margin expansion · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+13.1%TTM YoYB+Revenue +13.1% — above sector median, healthy trajectory · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.01totalAD/E 0.01 — essentially debt-free, pristine balance sheet · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E18.6xBP/E 18.6 — moderate premium, defensible with growth
PEG1.42proxyBPEG 1.42 — acceptable premium for growth · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $3.6b. Down 74% from 52-week high of $76.51 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median.
Moat
Net margin 30% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 19% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately.
Risk
Down 74% from the 52-week high — the market is pricing in something the screen can't see; verify the bear case before sizing up.
Horizon
1-3 yr $22.93 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $32.11 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $47.21 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.